Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

International Stem Cell (ISCO) Operating Expenses (2016 - 2025)

International Stem Cell (ISCO) has disclosed Operating Expenses for 16 consecutive years, with $789000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 65.23% to $789000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $4.0 million, a 55.48% decrease, with the full-year FY2023 number at $8.5 million, up 1.06% from a year prior.
  • Operating Expenses was $789000.0 for Q3 2025 at International Stem Cell, down from $905000.0 in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $2.5 million in Q3 2021 to a low of $789000.0 in Q3 2025.
  • A 5-year average of $2.0 million and a median of $2.2 million in 2021 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: rose 10.7% in 2024, then tumbled 65.23% in 2025.
  • International Stem Cell's Operating Expenses stood at $2.2 million in 2021, then rose by 9.37% to $2.4 million in 2022, then decreased by 2.36% to $2.3 million in 2023, then fell by 1.9% to $2.3 million in 2024, then crashed by 65.23% to $789000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Operating Expenses are $789000.0 (Q3 2025), $905000.0 (Q2 2025), and $2.3 million (Q1 2025).